We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Network meta‐analysis on the efficacy and safety of upadacitinib in adolescents and adults with moderate‐to‐severe atopic dermatitis.
- Authors
Qiu, Mei; Duan, Xue‐Yan; Yin, Dao‐Gen
- Abstract
Two articles1,2 recently published in I Lancet i revealed that upadacitinib was more effective than placebo for treatment of moderate-to-severe atopic dermatitis, regardless of with2 or without1 baseline use of topical corticosteroids. Risk ratio (RR) and 95% confidence interval (CI) were considered as treatment effects. Dear Editor, Upadacitinib is an oral Janus kinase (JAK) inhibitor and has a greater inhibitory effect on JAK1 than JAK2, JAK3, and tyrosine kinase 2.
- Subjects
ADULTS; ATOPIC dermatitis; TEENAGERS
- Publication
International Journal of Dermatology, 2022, Vol 61, Issue 1, pe24
- ISSN
0011-9059
- Publication type
Article
- DOI
10.1111/ijd.15850